Chinese antibody-drug conjugate developers are making further inroads in global biotech dealmaking, with Chengdu-based Biokine Therapeutics Ltd.’s US subsidiary recently inking a megadeal with Bristol Myers Squibb Company worth up to $8.4bn in total.
On 5 December, Hong Kong-listed WuXi Biologics saw a single-day share price plunge of over 23%, following a business update that revealed a broad set of challenges facing the overall Chinese biotech sector
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?